MA43049A - Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) - Google Patents

Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)

Info

Publication number
MA43049A
MA43049A MA043049A MA43049A MA43049A MA 43049 A MA43049 A MA 43049A MA 043049 A MA043049 A MA 043049A MA 43049 A MA43049 A MA 43049A MA 43049 A MA43049 A MA 43049A
Authority
MA
Morocco
Prior art keywords
receptor body
human cannabinoid
body antibodies
antibodies
cannabinoid
Prior art date
Application number
MA043049A
Other languages
English (en)
Inventor
Roger Ferrini
Anke Kretz-Rommel
Original Assignee
Bird Rock Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bird Rock Bio Inc filed Critical Bird Rock Bio Inc
Publication of MA43049A publication Critical patent/MA43049A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
MA043049A 2015-09-30 2016-09-27 Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) MA43049A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235194P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
MA43049A true MA43049A (fr) 2018-08-08

Family

ID=58424250

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043049A MA43049A (fr) 2015-09-30 2016-09-27 Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)

Country Status (20)

Country Link
US (2) US11421026B2 (fr)
EP (1) EP3356833A4 (fr)
JP (2) JP2019502651A (fr)
KR (1) KR102771076B1 (fr)
CN (2) CN114805574A (fr)
AU (2) AU2016330471B2 (fr)
BR (1) BR112018006633A2 (fr)
CA (1) CA3000167A1 (fr)
CL (1) CL2018000824A1 (fr)
CO (1) CO2018004569A2 (fr)
EC (1) ECSP18031407A (fr)
HK (1) HK1256286A1 (fr)
IL (2) IL300015A (fr)
MA (1) MA43049A (fr)
MX (1) MX2018003982A (fr)
PE (1) PE20181199A1 (fr)
RU (1) RU2727018C1 (fr)
TW (1) TWI784932B (fr)
WO (1) WO2017058771A1 (fr)
ZA (1) ZA201802807B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181199A1 (es) * 2015-09-30 2018-07-23 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
WO2018227200A1 (fr) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Procédé d'identification de composés utiles pour traiter une lipogenèse dérégulée, le diabète et autres troubles apparentés
WO2019211665A1 (fr) * 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations
CN111557913B (zh) * 2020-07-07 2022-05-31 中国科学院空天信息创新研究院 靶向癫痫细胞的纳米光敏复合物及调控检测系统
JPWO2023234406A1 (fr) * 2022-06-03 2023-12-07
CN119585311A (zh) * 2022-07-28 2025-03-07 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20060194260A1 (en) * 2003-02-18 2006-08-31 Astrazeneca Ab Screening assays for cannabinoid-ligand-type modulators of gpr55
JP2007527389A (ja) 2003-06-30 2007-09-27 メルク　エンド　カムパニー　インコーポレーテッド 放射性カンナビノイド−１受容体修飾因子
US20050095674A1 (en) * 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (fr) 2003-09-04 2005-03-17 Affibody Ab Nouvelle utilisation et nouveaux procedes associes
EP1574211A1 (fr) 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (fr) * 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection de biomarqueurs du recepteur cannabinoide et utilisations
EP1890767A2 (fr) 2005-05-27 2008-02-27 Pfizer Products Inc. Combinaison d'un antagoniste des recepteurs cannabinoides-1 et d'un inhibiteur des proteines microsomales de transfert de triglycerides pour traiter l'obesite ou maintenir une perte de poids
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007039797A1 (fr) * 2005-10-03 2007-04-12 Pfizer Products Inc. Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
CN101304654A (zh) * 2005-11-10 2008-11-12 艾尼纳制药公司 用于治疗肥胖和其相关症状的人类g蛋白-偶合受体和其调节剂
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (fr) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Composés modulant cb1 et utilisation de ces derniers
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
US8293211B2 (en) * 2007-06-11 2012-10-23 Makscientific, Llc CB1 receptor antagonists and uses thereof
EP2116556B1 (fr) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Anticorps contre récepteur de produit terminal de glycosylation (RAGE) et utilisations associées
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2593477A2 (fr) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Compositions pharmaceutiques et méthodes de traitement
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
PL2709631T3 (pl) * 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2013106349A1 (fr) * 2012-01-09 2013-07-18 The Board Of Trustees Of The University Of Arkansas Utilisation de l'aminoalkylindole jwh-073-m4 et composés apparentés comme antagonistes neutres des récepteurs aux cannabinoïdes de type 1 pour le traitement de l'alcoolisme, de l'abus de drogues, de l'obésité et des maladies liées à l'obésité
WO2013177418A1 (fr) * 2012-05-25 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de régulation de troubles et maladies associés à une activité de récepteur cannabinoïde
EP2698383B1 (fr) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Détection de cannabinoïdes synthétiques
CA2915386A1 (fr) * 2013-06-26 2014-12-31 Amgen Inc. Proteines de liaison a l'antigene se liant aux recepteurs cb1 et leurs utilisations
SG11201604664PA (en) 2013-12-12 2016-07-28 Stemcentrx Inc Novel anti-dpep3 antibodies and methods of use
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
PE20181199A1 (es) * 2015-09-30 2018-07-23 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano

Also Published As

Publication number Publication date
JP2019502651A (ja) 2019-01-31
AU2022291658A1 (en) 2023-02-02
CA3000167A1 (fr) 2017-04-06
EP3356833A1 (fr) 2018-08-08
TWI784932B (zh) 2022-12-01
CN108513615A (zh) 2018-09-07
IL258337A (en) 2018-05-31
JP2021176849A (ja) 2021-11-11
ZA201802807B (en) 2022-12-21
RU2727018C1 (ru) 2020-07-17
KR102771076B1 (ko) 2025-02-24
AU2016330471B2 (en) 2022-09-29
MX2018003982A (es) 2019-01-31
JP7262522B2 (ja) 2023-04-21
WO2017058771A8 (fr) 2018-04-19
CO2018004569A2 (es) 2018-11-22
US20180282406A1 (en) 2018-10-04
WO2017058771A1 (fr) 2017-04-06
CN114805574A (zh) 2022-07-29
AU2016330471A1 (en) 2018-04-26
CL2018000824A1 (es) 2019-04-12
HK1256286A1 (zh) 2019-09-20
EP3356833A4 (fr) 2019-04-10
IL258337B2 (en) 2023-06-01
ECSP18031407A (es) 2018-05-31
IL300015A (en) 2023-03-01
PE20181199A1 (es) 2018-07-23
TW201726733A (zh) 2017-08-01
US20230159634A1 (en) 2023-05-25
NZ741496A (en) 2025-05-02
CN108513615B (zh) 2022-03-08
BR112018006633A2 (en) 2018-10-23
KR20180117590A (ko) 2018-10-29
US11421026B2 (en) 2022-08-23

Similar Documents

Publication Publication Date Title
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
EP3709908A4 (fr) Ensemble poignet de réalité virtuelle
IL261200A (en) Antibodies specific to human poliovirus receptor (pvr)
EP3641762A4 (fr) Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
EP3436902A4 (fr) Système d'interface homme-ordinateur
EP3655432A4 (fr) Protéines de liaison 1
EP3399989A4 (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA47609A (fr) Anticorps anti-il31 à usage vétérinaire
EP3609568A4 (fr) Système d'élution de rubidium
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
EP3691971A4 (fr) Siège d'aéronef
CL2016002433A1 (es) Anticuerpos que se unen al receptor humano cannabinoide 1 (cb1)
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
EP3615820A4 (fr) Appareil d'assistance respiratoire
IL284807A (en) Antibodies specific to human nectin-2
EP3354420A4 (fr) Dispositif d'actionnement à biellette de type combiné
EP3396204A4 (fr) Dispositif d'actionnement de liaison
EP3401330A4 (fr) Anticorps empêchant la liaison vegf - nrp1
EP3578955A4 (fr) Système d'imagerie
IL279780A (en) Compositions and methods for agonizing the cb2 receptor
EP3688185A4 (fr) Dosage de liaison d'affinité numérique
EP3562740A4 (fr) Mât de liaison d'aéronef
FR3031502B1 (fr) Ensemble de pointage d'un instrument